Hydrix Limited (AU:HYD) has released an update.
Hydrix Limited reported a profitable quarter for its Services division, credited to strong sales contracts and reduced overhead costs, despite a slight dip in revenues. The company is optimistic about future growth, with a robust $40 million sales pipeline primarily from cardiac and medtech clients across Europe and the USA. Hydrix Medical is also expanding its sales pipeline, exploring new product opportunities in remote cardiac patient monitoring and ECG wearable devices.
For further insights into AU:HYD stock, check out TipRanks’ Stock Analysis page.